Latest News
argenx Unnatural Products Deal: What Does $550 Million Upfront Buy?
The argenx Unnatural Products deal buys a macrocyclic peptide discovery platform and its Santa Cruz research team. It also brings a portfolio of therapeutic macrocycles, none of which the companies have named. argenx will pay $550 million upfront in cash. Up to $595...
Latest News
Redrawing the Limits of “Undruggable” Proteins
For most of modern target-based drug discovery's history, many biologically important targets have been sidelined as undruggable proteins: structural scaffolds and transcription factors with no active site to inhibit, proteins presenting flat surfaces with no pocket...
Roche Hansoh ADC Deal: What Does Roche Get for $400 Million?
The Roche Hansoh ADC deal gives Roche rights outside Greater China to a portfolio of early antibody-drug conjugates. In return, Roche pays $400 million upfront and $110 million on the first anniversary. Hansoh Pharmaceutical announced the strategic collaboration and...
When Will Merck KGaA’s Silence Therapeutics Acquisition Close?
Merck KGaA, Darmstadt, Germany, expects the Silence Therapeutics acquisition to close in the first quarter of 2027. It will pay $20.00 in cash per American depositary share (ADS). That values Silence at about $1.3 billion. The companies announced the deal on 19...
Function Is the Endpoint: Why Aging Research Should Track Reserve
Ask older adults what they fear about aging and few of them name a number. They name the stairs. They name the low chair they cannot get out of, the groceries they cannot carry in from the car, the day they need someone's help to stay at home. That is the question...
Join The Future Of Life Sciences Media
In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.
Don’t wait for the media to pick up your story. Be the media.
Trending
More News
Weekly News Roundup | 10 August 2026
Life science news 10 August 2026: Curium pays up to $8 billion for Lantheus to build a radiopharma giant, AstraZeneca’s shares slide on reported $400 billion Bristol Myers Squibb talks, and the MHRA approves a first-in-class BTK inhibitor for chronic hives in an...
Beyond Cytotoxic Payloads: The Expansion of Non-traditional Conjugates
For over two decades, the narrative surrounding targeted biologics has been dominated by antibody-drug conjugates (ADCs) armed with cytotoxic small molecules designed to destroy cancer cells. While oncology remains a primary target for biologics, the therapeutic...
The Public Paper Trail: What Commercial Teams Find Out Last
For most of a decade, I worked on the commercial side of life sciences, and the same thing kept happening. Something would change at an account. A financing would close, a trial would move into a new phase, or a facility would receive an inspection observation. I...
Clinical Trials Roundup | 07 Aug 2026
Merck’s tulisokibart meets its primary and key secondary endpoints in a Phase 2 hidradenitis suppurativa study but misses in systemic sclerosis-associated interstitial lung disease, Eli Lilly’s olomorasib receives a second FDA Breakthrough Therapy designation in KRAS...
Why AI Pilots Fail in Life Sciences
Misaligned incentives, the wrong unit of work, and a probabilistic model where the process demands a reproducible one A draft annex to European GMP guidance, out for consultation until October 2025, contains the bluntest sentence yet written about AI in regulated...
Prevention by Design: How Korea’s Health System Diverges from America’s
South Korea and the United States are both wealthy, technologically sophisticated countries with excellent physicians and world-class hospitals. Yet they placed opposite structural bets on what a health system is for. America bet on treating disease as well as it can...
New Approach Methodologies: What Regulators Now Accept
New approach methodologies have moved from the margins of preclinical science to the centre of regulatory policy. Since publishing its Roadmap to Reducing Animal Testing in Preclinical Safety Studies in April 2025, the United States Food and Drug Administration has...
Evaluating Retrieval Systems for Clinical AI
Clinical decision support is not new, and it does not have to be complex to work. If anything, the simpler it is, the more likely clinicians are to use it. The best-known earlier example is the WHO surgical safety checklist, developed by a team led by Atul Gawande,...
Women-Led Biotech Is Outperforming. Why Is Capital Lagging?
A new therapeutic can take a decade. Often hundreds of millions of dollars. Regulators checking the work at every stage along the way. So when a category of founders consistently delivers better returns on less capital, you'd expect investment patterns to reflect...
CSRD Reporting: What Has Changed for European Biotech
The European Union has rewritten its sustainability disclosure rules. The consequences for the life sciences sector are substantial. CSRD reporting was once expected to capture tens of thousands of companies across the bloc. It now applies to a far smaller group of...
Microalgae Biomaterials: Where the Carbon Math Holds, and Where it Fails
A research team at the University of Colorado Boulder took a marine dinoflagellate called Pyrocystis lunula, mixed it into 4 wt% sodium alginate, crosslinked the gel ionically in calcium chloride, and extruded it through a Cellink BIO X bioprinter into printed grids...
NHS Golden Jubilee First Scottish Hospital to Adopt Steriwave
NHS Golden Jubilee Becomes First Scottish Hospital to Adopt Light-Activated Infection Prevention Technology to Prevent Surgical Site Infections GLASGOW — Scotland’s flagship orthopaedic hospital, NHS Golden Jubilee, has become the first in the country to adopt an...
Weekly News Roundup | 10 August 2026
Life science news 10 August 2026: Curium pays up to $8 billion for Lantheus to build a radiopharma giant, AstraZeneca’s shares slide on reported $400 billion Bristol Myers Squibb talks, and the MHRA approves a first-in-class BTK inhibitor for chronic hives in an...
Beyond Cytotoxic Payloads: The Expansion of Non-traditional Conjugates
For over two decades, the narrative surrounding targeted biologics has been dominated by antibody-drug conjugates (ADCs) armed with cytotoxic small molecules designed to destroy cancer cells. While oncology remains a primary target for biologics, the therapeutic...
The Public Paper Trail: What Commercial Teams Find Out Last
For most of a decade, I worked on the commercial side of life sciences, and the same thing kept happening. Something would change at an account. A financing would close, a trial would move into a new phase, or a facility would receive an inspection observation. I...
Clinical Trials Roundup | 07 Aug 2026
Merck’s tulisokibart meets its primary and key secondary endpoints in a Phase 2 hidradenitis suppurativa study but misses in systemic sclerosis-associated interstitial lung disease, Eli Lilly’s olomorasib receives a second FDA Breakthrough Therapy designation in KRAS...
Why AI Pilots Fail in Life Sciences
Misaligned incentives, the wrong unit of work, and a probabilistic model where the process demands a reproducible one A draft annex to European GMP guidance, out for consultation until October 2025, contains the bluntest sentence yet written about AI in regulated...
Prevention by Design: How Korea’s Health System Diverges from America’s
South Korea and the United States are both wealthy, technologically sophisticated countries with excellent physicians and world-class hospitals. Yet they placed opposite structural bets on what a health system is for. America bet on treating disease as well as it can...
New Approach Methodologies: What Regulators Now Accept
New approach methodologies have moved from the margins of preclinical science to the centre of regulatory policy. Since publishing its Roadmap to Reducing Animal Testing in Preclinical Safety Studies in April 2025, the United States Food and Drug Administration has...
Evaluating Retrieval Systems for Clinical AI
Clinical decision support is not new, and it does not have to be complex to work. If anything, the simpler it is, the more likely clinicians are to use it. The best-known earlier example is the WHO surgical safety checklist, developed by a team led by Atul Gawande,...
Women-Led Biotech Is Outperforming. Why Is Capital Lagging?
A new therapeutic can take a decade. Often hundreds of millions of dollars. Regulators checking the work at every stage along the way. So when a category of founders consistently delivers better returns on less capital, you'd expect investment patterns to reflect...
CSRD Reporting: What Has Changed for European Biotech
The European Union has rewritten its sustainability disclosure rules. The consequences for the life sciences sector are substantial. CSRD reporting was once expected to capture tens of thousands of companies across the bloc. It now applies to a far smaller group of...
Microalgae Biomaterials: Where the Carbon Math Holds, and Where it Fails
A research team at the University of Colorado Boulder took a marine dinoflagellate called Pyrocystis lunula, mixed it into 4 wt% sodium alginate, crosslinked the gel ionically in calcium chloride, and extruded it through a Cellink BIO X bioprinter into printed grids...
NHS Golden Jubilee First Scottish Hospital to Adopt Steriwave
NHS Golden Jubilee Becomes First Scottish Hospital to Adopt Light-Activated Infection Prevention Technology to Prevent Surgical Site Infections GLASGOW — Scotland’s flagship orthopaedic hospital, NHS Golden Jubilee, has become the first in the country to adopt an...
Featured Articles
Further News
Receptor.AI and Sethera Partner on AI-Guided Peptide Drug Discovery
Receptor.AI and Sethera Therapeutics Form Integrated Discovery Alliance for AI-Guided Polymacrocyclic Peptide Medicines Collaboration combines Sethera's proprietary enzymatic polymacrocyclisation and trillion-scale encoded screening with Receptor.AI's physics-based...
Dual and Triple Agonists Explained: GLP-1, GIP and Glucagon
Obesity and diabetes medicine has moved a long way from the single-hormone era. Dual and triple agonists are engineered molecules that switch on two or three hormone receptors at once. They now dominate the late-stage pipeline, and the highest doses tested have...
Ziltivekimab ZEUS Trial: What the Null Result Means
The ziltivekimab ZEUS trial has produced one of the more instructive negative results in recent cardiovascular medicine. Novo Nordisk announced headline results on 31 July 2026 showing that its once-monthly interleukin-6 inhibitor ziltivekimab lowered inflammation...
How the Gut-Brain-Metabolism Axis Is Reshaping Targeted Therapy
For decades, the fields of oncology, neuroscience, and microbiology operated in distinct silos within therapeutic research and clinical practice. Modern drug discovery, however, is rapidly witnessing a paradigm shift toward systemic biology. Researchers increasingly...
Singapore Radiopharmaceutical Market: How H2 2026 Looks
The Singapore radiopharmaceutical market enters the second half of 2026 with more clinical capacity, more research output and a heavier regulatory calendar than at any previous point. New imaging infrastructure came online at the end of 2025, first-in-human data from...
Why True Health Foods Need Evidence, Not Fashion
Functional foods have entered the mainstream, but adding a recognised ingredient is not the same as creating a credible product. A cardiologist argues that the category’s next phase will be won on scientific rationale, dose and honest communication, not on the length...
How Clinical Research Is Transforming the Future of Sarcoma Care
Rare cancers present one of the greatest challenges in modern oncology. Individually uncommon but collectively accounting for around one in five cancer diagnoses worldwide, they have historically attracted less research funding, fewer clinical trials and limited...
Weekly News Roundup | 03 August 2026
Life science news 3 August 2026: argenx pays $2.2 billion for what it calls a first-in-class anti-CD122 antibody, Johnson & Johnson strikes agreements worth up to $3.5 billion with in vivo CAR-T developer Sail Biomedicines, and GSK launches a £1.9 billion savings...
Personalized Cancer Care: How the Immune System is Reshaping Oncology
Immuno-oncology is not a new frontier, and for years, therapies like checkpoint inhibitors have reshaped how we treat certain cancers. While early approaches established that the immune system could fight cancer, the field has seen both major breakthroughs and clear...
FDA PreCheck Program: Seven Companies Chosen to Reshape US Manufacturing
The United States Food and Drug Administration has selected seven pharmaceutical and biotechnology companies for its FDA PreCheck Program, a pilot initiative designed to accelerate the establishment of new domestic drug manufacturing facilities. Announced on 7 August...
Retatrutide Phase 3 Data: Record Weight Loss, Unanswered Questions
Retatrutide, Eli Lilly’s investigational triple hormone receptor agonist, has now reported positive results across five Phase 3 trials. In the pivotal TRIUMPH-1 obesity study, participants on the highest dose lost an average of 28.3% of their body weight at 80 weeks,...
Responsible AI in Healthcare: Building Trust for Clinical Innovation
Artificial intelligence (AI) is rapidly transforming healthcare, moving beyond research laboratories into hospitals, clinics, and public health systems worldwide. Today, AI supports clinicians in areas such as medical imaging, clinical documentation, decision support,...
Further News
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.
Don’t wait for the media to pick up your story. Be the media.
See More Articles
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.












